Business Context and Reporting Period
This Form 8-K filing by Cerulean Pharma Inc. (not Dare Bioscience, Inc.) covers events occurring on May 26, 2015, and May 27, 2015. The report details significant changes in the company's executive leadership, specifically the departure of the principal financial officer and the appointment of an interim replacement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity figures. The document focuses exclusively on personnel changes and associated compensation arrangements.
Material Changes
- Departure of Principal Financial Officer: Karen L. Roberts, Senior Vice President of Finance and Administration, resigned effective August 31, 2015. Her resignation was not due to any disagreement with the company.
- Appointment of Interim CFO: Gregg Beloff was appointed as Interim Chief Financial Officer and principal financial officer, effective May 27, 2015.
- Compensation Arrangements:
- Ms. Roberts will receive a cash payment equal to six months of her 2015 annual base salary, up to six months of COBRA medical insurance premiums, and a 12-month extension to exercise vested stock options.
- Mr. Beloff was granted an option to purchase 90,000 shares of Common Stock, vesting in 12 equal monthly installments. The exercise price is the closing price on the grant date.
- Consulting Agreement: The company entered into a one-year consulting agreement with Danforth Advisors, LLC, to provide strategic and financial advice, including Mr. Beloff's services.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies. The primary focus is the transition of financial leadership to ensure continuity during the interim period.
Key Facts for Investor Verification
- Verify the exact separation date for Karen L. Roberts (August 31, 2015) and the duration of the transition period.
- Confirm the vesting schedule and exercise price for the 90,000 stock options granted to Gregg Beloff.
- Review the terms of the Separation Agreement with Ms. Roberts to understand the total cost of the transition.
- Note that the company name in the filing is Cerulean Pharma Inc., distinct from the "Dare Bioscience, Inc." mentioned in the request metadata.